St Jude Medical is participating in Heart Rhythm 2014, the Heart Rhythm Society’s Annual Scientific Sessions. Clinical evidence about the company’s cardiac rhythm management and ablation technologies will be provided in 38 sessions, including three late-breaking clinical trial sessions. The company’s latest technologies will be on display May 7-10 at the Moscone Convention Center in San Francisco, USA.
“St Jude Medical’s long-standing commitment to answering some of the medical community’s most challenging clinical questions about heart rhythm disorders and heart failure is reflected in a notable podium presence at the 2014 HRS Scientific Sessions,” says Mark D Carlson, chief medical officer for St Jude Medical. “We will continue investing in important research and developing technologies that reduce costs and improve patient outcomes.”
Key sessions in which new data regarding St. Jude Medical technologies will be presented include:
Late-Breaking Clinical Trial Sessions
Heart failure and abnormal heart rhythms are expensive epidemic diseases, and St Jude Medical is relentless in its quest to find novel treatments that benefit patients. Three important technologies from the company will be highlighted in this year’s Late Breaking Clinical Trial Sessions:
- Increased Adherence to Remote Monitoring is Associated with Reduced Mortality in Both Pacemaker and Defibrillator Patients: New findings on the Merlin remote monitoring system will be presented on May 8
- Dual-targeted Thoracic Spinal Cord Stimulation for Heart Failure as a Restorative Treatment (SCS HEART): First-in man Experience: Early findings will be presented on May 8. Products being evaluated are exclusively for clinical investigations and not being used in accordance with their approved indications for use.
- Chronic Performance of Leadless Cardiac Pacing: One Year Follow-up to the LEADLESS Trial: Chronic data about the Nanostim leadless pacemaker from the CE mark study will be presented on May 9. The Nanostim leadless pacemaker is being evaluated under a US Food and Drug Administration (FDA) Investigational Device Exception (IDE).
Quadripolar Pacing Technologies
St Jude Medical is the leader in quadripolar pacing technology, provided in our high voltage cardiac resynchronisation therapy defibrillator (CRT-D) devices since 2009 and now available with next-generation MultiPoint Pacing (MPP) technology and in a CRT pacemaker (CRT-P). To date, more than 100 clinical publications have provided broad evidence in support of the advantages of quadripolar technology from St Jude Medical. New research on the company’s Quadripolar technology will be presented in the following sessions:
- Reduced Mortality with Quadripolar Versus Bipolar Left Ventricular Leads in Cardiac Resynchronisation Therapy: Poster from Mintu Turakhia et al will be on display during the Featured Poster Session on May 7
- Reduced Costs Post CRT with Quadripolar LV leads compared to Bipolar LV leads: Poster from Raffaele Corbisiero et al will be on display during the Featured Poster Session on May 7
- Multipoint Left Ventricular Pacing in Cardiac Resynchronisation Therapy Patients Provides Similar Acute Haemodynamic Improvement Regardless of QRS Duration or Lead Location: Poster from Carlo Pappone et al will be on display on May 8. The Quadra Assura MP CRT-D is being evaluated under a US FDA IDE.
- Hospitalisation Rates and Associated Cost Analysis of Quadripolar versus Bipolar CRT-D: a comparative analysis of a single-center prospective Italian registry: Will be presented by Giovanni Forleo on May 9
The Durata defibrillation lead with Optim is supported by more than six years of implant experience and robust post-market surveillance monitoring. Important evidence regarding Optim and Durata high-voltage lead performance will be presented in the following sessions:
- Characterisation of the Biostability of Insulation Materials in Human Biologically Stressed Cardiac Leads: Will be presented by Bruce Wilkoff on May 8
- Electrical Survival Analysis of St Jude Medical Durata and Riata ST Optim High-Voltage Leads from the VA National Cardiac Device Surveillance Program: Poster from Seema Pursnani et al will be on display on May 8
- Optim ICD Lead Failures: Long-term Rates from Independent Analysis of 11,016 Leads in 3 Prospective Registries: Poster from John Cairns et al will be on display on May 9
The TactiCath irrigated ablation catheter provides physicians with a real-time, objective measure of the force they apply to the heart wall during a catheter ablation procedure. Data from the TOCCASTAR trial, a US FDA IDE for TactiCath, will be included in the following presentations:
- Force Sensing Ablation Catheters: Have Our Hopes Been Realised?: New information from the TOCCASTAR trial will be presented during the Atrial Fibrillation Summit by Moussa Mansour on May 7
- Optimal Contact Force During Pulmonary Vein Isolation Improves Chronic Freedom from Recurrence of Atrial Fibrillation: Poster from Moussa Mansour with data will be on display on May 9
- Steerable Sheath Promotes Improved Contact Force Parameters During Pulmonary Vein Isolation: Poster from Frank Cuoco with data will be on display on May 10